Table 1:
Baseline characteristics and laboratory findings with posttreatment changes.
Group
Placebo
Fenofibrate
Rosiglitazone
Combined
ANOVA
𝑁
=
1
0
𝑁
=
9
𝑁
=
8
𝑁
=
7
Rank
Mean ± SD
Mean ± SD
Mean ± SD
Mean ± SD
𝑃
-value
Age
5
7
.
4
±
1
1
.
1
6
1
.
2
±
1
1
.
6
5
7
.
3
±
8
.
4
5
4
.
7
±
9
.
5
M : F
6 : 4
3 : 6
5 : 3
3 : 4
Pre-TG
2
0
6
±
6
5
2
7
8
±
1
2
6
2
3
4
±
5
8
2
3
9
±
7
3
𝑃
=
0
.
2
1
2
Post-TG
2
0
2
±
5
3
1
9
2
±
6
4
2
4
0
±
1
1
5
1
7
2
±
2
7
(%Δ)
(
7
.
6
%
±
5
1
.
0
%
)
(
−
2
.
2
%
±
2
6
.
0
%
)
(
7
.
4
%
±
4
8
.
9
%
)
(
2
0
.
0
%
±
3
6
.
5
%
)
Pre-HDL-C
4
8
±
9
4
1
±
8
5
2
±
1
9
5
2
±
1
4
𝑃
=
0
.
3
4
2
Post-HDL-C
4
8
±
9
4
7
±
7
5
0
±
1
7
5
3
±
9
(%Δ)
(
1
.
7
%
±
1
0
.
5
%
)
(
1
4
.
5
%
±
2
1
.
6
%
)
(
1
.
9
%
±
2
4
.
6
%
)
(
5
.
8
%
±
1
6
.
4
%
)
Pre-LDL-C
1
2
4
±
4
6
1
1
1
±
4
0
1
4
5
±
2
4
.
6
%
1
0
6
±
4
1
𝑃
=
0
.
6
9
2
Post-LDL-C
1
2
8
±
3
9
1
1
8
±
3
2
1
4
0
±
4
1
1
0
2
±
3
1
(%Δ)
(
1
3
.
7
%
±
4
7
.
8
%
)
(
2
.
6
%
±
2
9
.
3
%
)
(
−
.
5
%
±
2
7
.
4
%
)
(
3
7
.
3
%
±
1
4
1
.
6
%
)
± pre-Tot C
2
0
4
.
4
±
5
7
.
9
2
1
3
.
6
±
3
9
.
0
2
3
8
.
4
±
3
9
.
5
2
1
5
.
7
±
3
6
.
6
𝑃
=
0
.
3
7
2
Post-Tot C
2
2
7
.
4
±
3
7
.
2
1
9
9
.
0
±
5
1
.
2
2
3
0
.
9
±
5
2
.
2
2
0
1
.
1
±
3
6
.
5
(%Δ)
(
2
5
.
8
%
±
7
0
.
2
%
)
(
−
7
.
7
%
±
2
6
.
1
%
)
(
−
2
.
3
%
±
2
1
.
3
%
)
(
−
5
.
0
%
±
2
1
.
6
%
)